C. Yurdaydin Et Al. , "A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis-end of treatment results from the LOWR HDV-2 study," International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver , vol.66, Amsterdam, Netherlands, 2017
Yurdaydin, C. Et Al. 2017. A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis-end of treatment results from the LOWR HDV-2 study. International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver , (Amsterdam, Netherlands).
Yurdaydin, C., Idilman, R., Keskin, O., Kalkan, C., Karakaya, M. F., Caliskan, A., ... Yurdcu, E.(2017). A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis-end of treatment results from the LOWR HDV-2 study . International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Amsterdam, Netherlands
Yurdaydin, C. Et Al. "A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis-end of treatment results from the LOWR HDV-2 study," International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Amsterdam, Netherlands, 2017
Yurdaydin, C. Et Al. "A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis-end of treatment results from the LOWR HDV-2 study." International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver , Amsterdam, Netherlands, 2017
Yurdaydin, C. Et Al. (2017) . "A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis-end of treatment results from the LOWR HDV-2 study." International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver , Amsterdam, Netherlands.
@conferencepaper{conferencepaper, author={C. Yurdaydin Et Al. }, title={A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis-end of treatment results from the LOWR HDV-2 study}, congress name={International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver}, city={Amsterdam}, country={Netherlands}, year={2017}}